MicroRNA therapeutics in neurological disease
Related Experiment Video
Updated: May 2, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
David S Greenberg, Hermona Soreq1
1Dept of Biological Chemistry and the Edmond and Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Israel 91904. david.greenberg1@mail.huji.ac.il.
Abstract:
Developing microRNA therapeutics for neurological diseases is both a promising opportunity and an extremely challenging topic for several reasons. The promise stems from the very small size of microRNAs, which makes them amenable for manipulation via short synthetic oligonucleotides or engineered viruses. Also, the fact that each microRNA may regulate numerous target transcripts of the same pathway predicts that such manipulations may affect an entire pathway rather than a single gene and gives reason to hope that low dose therapeutic targeting of the top microRNA in such a hierarchic pyramid would suffice to induce a focused change in the entire pyramid. However, these same features, which make microRNAs such promising targets for therapeutic manipulations also present great challenges. Thus the plethora of functional targets for each microRNA in specific cell types is yet far from being elucidated, which implies that the targets to be affected may not be those planned to be manipulated (a risk of 'off-target' effects). Also, the hierarchic order of microRNA regulation is yet unknown, which predicts a risk of complex, multi-leveled consequences following the manipulation of a single microRNA; and the delivery of oligonucleotide therapeutics into the brain is a challenge due to the blood-brain barrier. In this chapter, we briefly outline the current state of knowledge regarding microRNA regulation in different neuropathologies and sketch the emerging principles for the development of microRNA therapeutics for these diseases.We address issues such as modes of delivery and consideration of the inherited and acquired variability between individuals in the susceptibility to such treatments. We further refer in a somewhat more in-depth manner to the issue of manipulating microRNA functioning in the parasympathetic system and the pathway of cholinergic signaling. Beyond the brain and within it, cholinergic signaling controls inflammatory reactions, and microRNA changes would likely affect this function as well. Furthermore, microRNA regulation of cholinergic signaling involves the elements of complexity and hierarchy noted above, and is relevant to numerous neuropathologies and neurodegenerative syndromes. Research and translational efforts that lead to the development of microRNA therapeutics merit thorough discussion.
Insights
Developing microRNA therapeutics for neurological diseases offers promise but faces challenges. MicroRNAs (miRNAs) can regulate entire pathways, but off-target effects and delivery across the blood-brain barrier remain significant hurdles for effective treatment.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- MicroRNAs (miRNAs) are small regulatory molecules with potential for treating neurological diseases.
- Their ability to regulate multiple targets within a pathway offers a promising therapeutic avenue.
- However, challenges include understanding complex regulatory networks and efficient brain delivery.
Purpose of the Study:
- To review the current understanding of miRNA regulation in neuropathologies.
- To outline principles for developing miRNA therapeutics for neurological disorders.
- To discuss delivery methods and individual variability in treatment response.
Main Methods:
- Review of existing literature on miRNA function in neuropathologies.
- Analysis of challenges in miRNA therapeutic development, including off-target effects and delivery.
- Focus on miRNA regulation within the parasympathetic and cholinergic systems.
Main Results:
- miRNAs hold promise for pathway-focused neurological treatments.
- Significant challenges exist, including elucidating all functional targets and understanding hierarchical regulation.
- The blood-brain barrier presents a major obstacle for oligonucleotide delivery.
Conclusions:
- Developing miRNA therapeutics for neurological diseases requires addressing complex regulatory networks and delivery challenges.
- Understanding miRNA's role in cholinergic signaling is crucial for treating various neuropathologies.
- Further research and translational efforts are essential for advancing miRNA-based therapies.
More Related Videos
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
Microorganisms in Medicine and Therapeutics
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

